Hayes RL, Arbit E, Odaimi M, Pannullo S, Scheff R, Kravchinskiy
D & Zaroulis C. 2001. Adoptive cellular immunotherapy for the
treatment of malignant gliomas. Critical Rev Oncol/Hematol
39:31-42.
Huang Y, Hayes RL, Wertheim S, Arbit E & R Scheff. 2001.
Treatment of refractory malignant glioma with adoptive
immunotherapy: A case report. Critical Rev Oncol/Hematol
39:17-23.
Castellanos M, Weinstein G, & Hayes RL. 2001. A rapid method
to identify cytotoxic T-lymphocyte peptide epitopes from HLA-A2(+)
donors. Critical Rev Oncol/Hematol 57:133-8.
Castellanos M, Maiman M, & Hayes RL. 2001. Synthetic
peptides induce a cytotoxic response against human papillomavirus
type-18. Gynecol Oncol 82:77-83.
Musella A, Levin M, Selker RG, Fried A, Schulder M, Williams J,
Arbit E, Hayes RL & Lederman G. Virtual trials and
tribulations- An internet registry of brain tumor treatments.
Newcomb EW, Cohen H, Lee SR, Bhalla SK, Bloom J, Hayes RL &
DC Miller. 1998. Survival of patients with glioblastoma multiforme
is not influenced by altered expression of p16, p53, EGFR, MDM2 or
Bcl-2 genes. Brain Pathol 8:1998.
Newcomb EW, Bhalla SK, Parrish CL, Hayes RL, Cohen H & DC
Miller. 1997. Bcl-2 protein expression in astrocytomas in relation
to patient survival and p53 gene status. Acta Neuropath
94:369-75.
Moscatello DK, Holgado-Madruga M, Godwin AK, Ramirez G, Gunn G,
Zoltick PW, Biegel JA, Hayes RL & AJ Wong. 1995. Frequent
expression of a mutant epidermal growth factor receptor in multiple
human tumors. Cancer Res 55:5536-9
Hayes RL, Koslow M, Hiesiger EM, Hymes KB, Hochster HS, Moore
EJ, Pierz DM, Chen DK, Budzilovich GN & J Ransohoff. 1995.
Improved long-term survival following intracavitary interleukin-2
(IL-2) and lymphokine activated killer cells for adults with
recurrent malignant glioma. Cancer 76: 840-52.
Allen JC & RL Hayes. 1994. Selected immunotherapy studies of
the interferons and IL-2/LAK cells. In: Brain Tumors in Children:
Principles of Diagnosis and Treatment, 2nd edition. Cohen ME, &
PK Duffner (eds.), NY: Raven Press, Ltd., pp. 161-75.
Hiesiger EM, Hayes RL, Pierz DM & GN Budzilovich. 1993.
Prognostic relevance of epidermal growth factor receptor (EGF-R)
and c-neu/erbB2 expression in glioblastomas (GBMs). J Neuro-Oncol
16:93-104.
Hayes RL. 1992. The cellular immunotherapy of primary brain
tumors. Revue Neurol 148:454-66.
Hiesiger EM, Hayes RL, Thoron L, Budzilovich GN, Pierz DM, Wise
A, & J Ransohoff. 1991. Expression of epidermal growth factor
receptor (EGF-R) and erb-B2 (HER 2/neu) in glioblastoma (GBM):
Prognostic relevance. Develop in Oncol 66:105-7.
Hayes RL, Koslow M, Hiesiger EM, Hochster H, Hymes K, Moore E,
Pierz DM, Wise A & J Ransohoff. 1991. Biologic response to
intracavitary Interleukin-2/ lymphokine activated killer (LAK)
cells in the treatment of primary malignant brain tumors. Develop
in Oncol 66:225-227.
Beller U, Chachoua A, Speyer JL, Sorich J, Dugan M, Liebes L,
Hayes RL & M Beckman. 1989. Phase IB study of low-dose
intraperitoneal recombinant Interleukin-2 in patients with
refractory advanced ovarian cancer: Rationale and preliminary
report. Gynecol Oncol 34:407-12.
Plate JMD, Lukaszewska TL, Bustamante G & RL Hayes. 1988.
Cytokines involved in the generation of cytolytic effector T
lymphocytes. Ann NY Acad Sci 532:149-57.
Plate JMD, McMannis JD & RL Hayes. 1985. Identification of a
helper cell activation complex (HAC) expression and its
relationship to Interleukin-1 function. In: The Physiologic,
Metabolic, and Immunologic Actions of Interleukin-1, Alan Liss, NY
pp. 339-348.
Hayes RL & HN Claman. 1983. Pretreatment with minor
histocompatibility complex antigens prevents the development of
functional CTL helper cell activity. J Immunol 130:56-9.
Hayes RL & HN Claman. 1982. The induction of alloreactive
responses in vivo are inhibited by pre-treatment with Mls-disparate
cells. J Immunol 129:232-4.
Hayes RL. 1982. Ph.D. Thesis: Pretreatment of mice in vivo with
Mls-disparate minor histocompatibility antigens prevents the
generation of alloreactive cytotoxic T lymphocytes.
Moorhead JW, Murphy JW, Harvey RP, Hayes RL & TJ Fetterhoff.
1982. Soluble factors in tolerance and contact sensitivity to
2,4-dinitrofluoro-benzene in mice. IV. Characterization of
migration inhibition factor producing lymphocytes and genetic
requirements for activation. Eur J Immunol 12: 431-6.
Zlotnik A, Vatter A, Hayes RL, Blumenthal E & AJ Crowle.
1982. Mouse pleural macrophages: Characterization and comparison
with mouse alveolar and peritoneal macrophages. J Reticuloendothel
Soc 31: 207-20.